Related Experiment Video
Updated: May 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Comparative cardiometabolic effects of fibrates and omega-3 fatty acids
Seung Hwan Han1, Pyung Chun Oh, Soo Lim
1Gachon University Gil Medical Center, Incheon, Republic of Korea.
Insights
Statin therapy lowers LDL cholesterol but residual cardiovascular risk persists. This review examines fibrates and omega-3 fatty acids for reducing this risk, comparing recent trial results.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Science
Background:
- Despite statin therapy, residual cardiovascular risk remains high.
- Triglycerides and high-density lipoprotein cholesterol are key targets for cardiovascular disease prevention.
- Fibrates and omega-3 fatty acids offer potential benefits but have controversial findings.
Purpose of the Study:
- To review the vascular and metabolic effects of fibrates and omega-3 fatty acids.
- To analyze recent randomized clinical trial results for these therapies.
- To compare their efficacy in reducing residual cardiometabolic risk under current guidelines.
Main Methods:
- Literature review of scientific studies and clinical trials.
- Analysis of vascular and metabolic effects of fibrates and omega-3 fatty acids.
- Comparison of recent trial outcomes with historical data.
Main Results:
- Fibrates and omega-3 fatty acids impact triglycerides and high-density lipoprotein cholesterol.
- Recent trials show varied results, necessitating updated understanding.
- These agents demonstrate anti-atherosclerotic, vascular, and metabolic effects.
Conclusions:
- Fibrates and omega-3 fatty acids are considered for residual cardiovascular risk reduction.
- Recent clinical trial data requires careful interpretation alongside existing knowledge.
- Further research is needed to optimize their use in modern cardiovascular disease management.
Abstract:
Even with the aggressive reduction of low-density lipoprotein cholesterol by statin therapy, a high residual risk of cardiovascular events remains substantially and attracts attention to the need for additional preventive therapies. Therefore, effective reductions of residual risk of cardiovascular disease have emerged as therapeutic targets. Fibrates and omega-3 fatty acids have been introduced to reduce triglycerides and to increase high-density lipoprotein cholesterol and have shown anti-atherosclerotic, vascular and metabolic effects. However, some effects are controversial and very recent randomized clinical trials report different results from the earlier ones. In this review, we address the vascular and metabolic effects and the results of recent clinical trials of fibrates and omega-3 fatty acids. We also compared their effects under modern guideline therapy regarding potential drugs to reduce a residual cardiometabolic risk of cardiovascular disease.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Structure of Lipids
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
